Vivos Treats Sleep Apnea Without CPAP | FDA-Cleared Device Expands Airway Non-Surgically

For healthcare investors and patients seeking alternatives to CPAP, this New to The Street interview features Kirk Huntsman, CEO of Vivos Therapeutics, explaining how the company’s FDA-cleared oral appliance and integrated treatment protocol remodel the human airway non-surgically to treat obstructive sleep apnea in adults and children, a condition affecting nearly 100 million Americans and linked to diabetes, cardiovascular disease, dementia, and other comorbidities, while offering a one-time treatment completed in about 9–12 months that can restore breathing and sleep quality for life. #NewToTheStreet #VivosTherapeutics #SleepApnea #OSA #CPAPAlternative #MedicalDevice #HealthcareInnovation #AirwayHealth #PatientCare #FDAcleared #HealthTech #PreventiveHealth #Biotech #MedicalInvesting